October 2019 – Alma receives the EMA’s CHMP (Committee for Medicinal Products for Human Use) scientific advice. The Agency’s advice concerned quality development, pre-clinical development and clinical development for the product ALM-101 for treatment of moderate to severe ulcerative colitis.
